Sionna Therapeutics Q2 net loss widens

Sionna Therapeutics

06/08/2026 12:19

Overview
US biopharmaceutical firm's Q2 net loss increased yr/yr
Operating expenses for Q2 rose, driven by higher R&D and personnel costs
Company expects cash position to fund operations into 2028

Outlook
Company expects cash position to fund operations into 2028

Result Drivers
PIPELINE ADVANCEMENT - Co said increased R&D expenses were mainly driven by development costs to advance clinical pipeline
PERSONNEL COSTS - Co said higher operating expenses were partly due to personnel-related costs, including stock-based compensation

Company press release: ID:nGNX6mjMFR

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$29.89 mln
$29.22 mln (10 Analysts)
Q2 Income from Operations
 
-$32.47 mln
 
Q2 Loss Per Basic Share
 
$0.66
 
Q2 Operating Expenses
 
$32.47 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sionna Therapeutics, Inc. is $54.00, about 14.1% above its August 5 closing price of $47.34

Reuters Recommended Reads
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)